MedTrace Logo

Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome

NCT02711306 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-10-29

Study results available
· View outcomes & findings →

Summary

Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Glucomannan noodle

The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.

DIETARY_SUPPLEMENT

Placebo noodle

In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.

Sponsors & Collaborators

  • Taipei Medical University

    lead OTHER

Principal Investigators

  • Chih-Han Lin, MS · Office of Human Research, Taipei Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-01-31
Completion
2014-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711306 on ClinicalTrials.gov